Long Beach, CALIFORNIA3 Active Studies

Osteogenesis Imperfecta Clinical Trials in Long Beach, CALIFORNIA

Find 3 actively recruiting osteogenesis imperfecta clinical trials in Long Beach, CALIFORNIA. Connect with local research sites and explore new treatment options.

3
Active Trials
3
Sponsors
3,050
Enrolling

Recruiting Osteogenesis Imperfecta Studies in Long Beach

About Osteogenesis Imperfecta Clinical Trials in Long Beach

Osteogenesis imperfecta is a group of genetic disorders mainly affecting the bones, causing them to break easily, often from little or no apparent cause. It is caused by defects in collagen production. Treatment includes bisphosphonates, physical therapy, and surgical rodding.

There are currently 3 osteogenesis imperfecta clinical trials recruiting participants in Long Beach, CALIFORNIA. These studies are seeking a combined 3,050 participants. Research is being sponsored by National Cancer Institute (NCI), VA Office of Research and Development, PedAL BCU, LLC. Clinical trial participation is free and participants receive study-related medical care at no cost.

Osteogenesis Imperfecta Clinical Trials in Long Beach — FAQ

Are there osteogenesis imperfecta clinical trials in Long Beach?

Yes, there are 3 osteogenesis imperfecta clinical trials currently recruiting in Long Beach, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Long Beach?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Long Beach research site will contact you about next steps.

Are clinical trials in Long Beach free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Long Beach studies also compensate for your time and travel.

What osteogenesis imperfecta treatments are being tested?

The 3 active trials in Long Beach are testing new therapies including novel drugs, biologics, and treatment approaches for osteogenesis imperfecta.

Data updated March 2, 2026 from ClinicalTrials.gov